Trevi is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
Founded in 2011, Trevi is headquartered in New Haven, CT.
Location: United States, Connecticut, New Haven
Employees: 11-50
Total raised: $129.5M
Founded date: 2011
Investors 4
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| - | Omega Fund... | omegafunds... |
| - | Aperture V... | aperturevp... |
| - | TPG | tpg.com |
Funding Rounds 6
| Date | Series | Amount | Investors |
| 15.10.2021 | - | $3M | New Enterp... |
| 21.07.2017 | Series C | $50.5M | New Enterp... |
| 08.01.2015 | - | $15M | - |
| 06.11.2014 | Series B | $26M | - |
| 04.06.2014 | Series B | $25M | - |
| 18.12.2012 | Series A | $10M | - |
Mentions in press and media 27
| Date | Title | Description |
| 07.05.2024 | Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates | Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the second half of 2024 Topline results continue to be expected in the first half of 20... |
| 09.04.2024 | Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference | Professor Jacky Smith will present on the reduction of cough bouts with nalbuphine ER observed in patients with IPF in the CANAL trial NEW HAVEN, Conn., April 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage... |
| 20.03.2024 | Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates | Reaffirms guidance for the Phase 2a RIVER trial of Haduvio in RCC patients with topline data expected in the second half of 2024 Enrollment progressing in the Phase 2b CORAL dose-ranging trial of Haduvio for the treatment of chronic cough i... |
| 14.07.2022 | Traders News Source Senior Editor Mark Roberts Interviews Jennifer Good CEO of Trevi Therapeutics | NEW YORK, NY / ACCESSWIRE / July 14, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Trevi Thera... |
| 05.01.2022 | Trevi Therapeutics Announces Clinical Trial Updates for Lead Indications | NEW HAVEN, Conn., Jan. 5, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated con... |
| 11.11.2021 | Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update | NEW HAVEN, Conn., Nov. 10, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to t... |
| 15.10.2021 | Trevi Therapeutics, Inc. announced that it expects to receive $3 million in funding from New Enterprise Associates, Inc. | Trevi Therapeutics, Inc. announced that it has entered into a securities purchase agreement with existing investor, New Enterprise Associates 16, L.P., a fund managed by New Enterprise Associates, Inc. in a private placement to issue 1,851,... |
| 01.10.2021 | Trevi Therapeutics : Announces $11.8 Million Private Placement Priced At-the-Market | NEW HAVEN, Conn., Sept. 30, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to ... |
| 12.08.2021 | Trevi Therapeutics Announces Second Quarter 2021 Financial Results and Business Update | |
| 12.08.2021 | Trevi Therapeutics : Announces Second Quarter 2021 Financial Results and Business Update | NEW HAVEN, Conn., Aug. 12, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy Haduvio™ (nalbuphine ER) to t... |
Show more